WEBVTT
Kind: captions
Language: en

00:00:12.440 --> 00:00:16.070 

the<00:00:13.440> idea<00:00:13.740> of<00:00:14.089> genealogy<00:00:15.089> pediatric<00:00:15.719> diseases

00:00:16.070 --> 00:00:16.080 
the idea of genealogy pediatric diseases

00:00:16.080 --> 00:00:18.019 
the idea of genealogy pediatric diseases
and<00:00:16.529> experimental<00:00:17.340> surgery

00:00:18.019 --> 00:00:18.029 
and experimental surgery

00:00:18.029 --> 00:00:21.560 
and experimental surgery
includes<00:00:18.510> eight<00:00:18.810> research<00:00:19.470> groups<00:00:20.300> the<00:00:21.300> spine

00:00:21.560 --> 00:00:21.570 
includes eight research groups the spine

00:00:21.570 --> 00:00:23.720 
includes eight research groups the spine
research<00:00:22.050> group<00:00:22.350> which<00:00:22.619> I'm<00:00:22.830> leading<00:00:23.189> divide

00:00:23.720 --> 00:00:23.730 
research group which I'm leading divide

00:00:23.730 --> 00:00:26.480 
research group which I'm leading divide
our<00:00:23.939> work<00:00:23.970> in<00:00:24.480> four<00:00:24.930> main<00:00:25.350> research<00:00:25.890> areas

00:00:26.480 --> 00:00:26.490 
our work in four main research areas

00:00:26.490 --> 00:00:28.609 
our work in four main research areas
the<00:00:27.000> first<00:00:27.269> one<00:00:27.510> is<00:00:27.750> adolescent<00:00:28.410> idiopathic

00:00:28.609 --> 00:00:28.619 
the first one is adolescent idiopathic

00:00:28.619 --> 00:00:32.269 
the first one is adolescent idiopathic
scoliosis<00:00:29.160> in<00:00:30.000> 2013<00:00:30.900> has<00:00:31.500> generated<00:00:32.099> very

00:00:32.269 --> 00:00:32.279 
scoliosis in 2013 has generated very

00:00:32.279 --> 00:00:34.370 
scoliosis in 2013 has generated very
relevant<00:00:32.730> information<00:00:33.510> in<00:00:33.719> the<00:00:33.930> field<00:00:34.170> of

00:00:34.370 --> 00:00:34.380 
relevant information in the field of

00:00:34.380 --> 00:00:37.400 
relevant information in the field of
body<00:00:34.680> image<00:00:35.160> perception<00:00:35.880> and<00:00:36.059> has<00:00:36.750> created<00:00:37.290> a

00:00:37.400 --> 00:00:37.410 
body image perception and has created a

00:00:37.410 --> 00:00:40.940 
body image perception and has created a
new<00:00:37.710> scale<00:00:38.070> our<00:00:38.540> second<00:00:39.540> research<00:00:40.170> areas<00:00:40.710> are

00:00:40.940 --> 00:00:40.950 
new scale our second research areas are

00:00:40.950 --> 00:00:43.970 
new scale our second research areas are
the<00:00:41.219> spinal<00:00:41.670> deformity<00:00:42.210> since<00:00:42.870> 2010<00:00:43.559> is

00:00:43.970 --> 00:00:43.980 
the spinal deformity since 2010 is

00:00:43.980 --> 00:00:46.010 
the spinal deformity since 2010 is
leading<00:00:44.489> the<00:00:44.760> unique<00:00:45.210> European

00:00:46.010 --> 00:00:46.020 
leading the unique European

00:00:46.020 --> 00:00:49.160 
leading the unique European
multicenter<00:00:46.950> and<00:00:47.129> prospective<00:00:47.520> database<00:00:48.390> for

00:00:49.160 --> 00:00:49.170 
multicenter and prospective database for

00:00:49.170 --> 00:00:52.040 
multicenter and prospective database for
adult<00:00:49.649> spinal<00:00:50.039> deformity<00:00:50.719> secondly<00:00:51.719> we<00:00:52.020> are

00:00:52.040 --> 00:00:52.050 
adult spinal deformity secondly we are

00:00:52.050 --> 00:00:55.069 
adult spinal deformity secondly we are
assessing<00:00:52.739> all<00:00:53.160> preoperative<00:00:54.079> complication

00:00:55.069 --> 00:00:55.079 
assessing all preoperative complication

00:00:55.079 --> 00:00:58.340 
assessing all preoperative complication
and<00:00:55.260> risks<00:00:55.890> in<00:00:56.070> adult<00:00:56.579> deformity<00:00:57.270> surgery<00:00:57.350> to

00:00:58.340 --> 00:00:58.350 
and risks in adult deformity surgery to

00:00:58.350 --> 00:01:00.410 
and risks in adult deformity surgery to
produce<00:00:58.770> an<00:00:59.010> algorithm<00:00:59.670> for<00:01:00.059> surgical

00:01:00.410 --> 00:01:00.420 
produce an algorithm for surgical

00:01:00.420 --> 00:01:03.200 
produce an algorithm for surgical
treatment<00:01:00.570> our<00:01:01.230> third<00:01:01.739> research<00:01:02.309> area<00:01:02.760> is<00:01:03.000> now

00:01:03.200 --> 00:01:03.210 
treatment our third research area is now

00:01:03.210 --> 00:01:06.109 
treatment our third research area is now
running<00:01:03.600> a<00:01:03.870> trial<00:01:04.470> to<00:01:05.070> compare<00:01:05.309> mesenchymal

00:01:06.109 --> 00:01:06.119 
running a trial to compare mesenchymal

00:01:06.119 --> 00:01:09.350 
running a trial to compare mesenchymal
stem<00:01:06.540> cells<00:01:07.020> in<00:01:07.710> mobilized<00:01:08.280> inborn<00:01:08.820> allograph

00:01:09.350 --> 00:01:09.360 
stem cells in mobilized inborn allograph

00:01:09.360 --> 00:01:12.859 
stem cells in mobilized inborn allograph
versus<00:01:10.320> of<00:01:10.530> polymers<00:01:11.220> bone<00:01:11.729> graft<00:01:12.060> in<00:01:12.420> spinal

00:01:12.859 --> 00:01:12.869 
versus of polymers bone graft in spinal

00:01:12.869 --> 00:01:14.570 
versus of polymers bone graft in spinal
fusion<00:01:13.409> and<00:01:13.590> then<00:01:13.920> our<00:01:14.189> anesthesiologist

00:01:14.570 --> 00:01:14.580 
fusion and then our anesthesiologist

00:01:14.580 --> 00:01:17.660 
fusion and then our anesthesiologist
group<00:01:15.240> and<00:01:15.479> the<00:01:15.960> main<00:01:16.200> four<00:01:16.890> on<00:01:17.100> the<00:01:17.280> main<00:01:17.430> goal

00:01:17.660 --> 00:01:17.670 
group and the main four on the main goal

00:01:17.670 --> 00:01:19.880 
group and the main four on the main goal
of<00:01:17.880> this<00:01:18.210> area<00:01:18.689> is<00:01:18.780> the<00:01:18.930> identification<00:01:19.409> of

00:01:19.880 --> 00:01:19.890 
of this area is the identification of

00:01:19.890 --> 00:01:22.249 
of this area is the identification of
patients<00:01:20.430> at<00:01:20.520> risk<00:01:20.790> and<00:01:21.110> development<00:01:22.110> of

00:01:22.249 --> 00:01:22.259 
patients at risk and development of

00:01:22.259 --> 00:01:24.800 
patients at risk and development of
guidelines<00:01:22.950> to<00:01:23.100> prevent<00:01:23.549> allergenic<00:01:24.390> blood

00:01:24.800 --> 00:01:24.810 
guidelines to prevent allergenic blood

00:01:24.810 --> 00:01:27.469 
guidelines to prevent allergenic blood
transfusion<00:01:25.590> the<00:01:26.280> musculoskeletal<00:01:26.790> tissue

00:01:27.469 --> 00:01:27.479 
transfusion the musculoskeletal tissue

00:01:27.479 --> 00:01:30.770 
transfusion the musculoskeletal tissue
engineering<00:01:27.960> research<00:01:28.530> group<00:01:28.799> led<00:01:29.130> by<00:01:29.780> dr.

00:01:30.770 --> 00:01:30.780 
engineering research group led by dr.

00:01:30.780 --> 00:01:32.840 
engineering research group led by dr.
Mario's<00:01:31.140> are<00:01:31.290> given<00:01:31.650> they<00:01:32.130> are<00:01:32.159> running<00:01:32.490> to

00:01:32.840 --> 00:01:32.850 
Mario's are given they are running to

00:01:32.850 --> 00:01:34.850 
Mario's are given they are running to
play<00:01:33.060> clinical<00:01:33.509> studies<00:01:33.900> and<00:01:34.079> a<00:01:34.439> clinical

00:01:34.850 --> 00:01:34.860 
play clinical studies and a clinical

00:01:34.860 --> 00:01:37.160 
play clinical studies and a clinical
trial<00:01:35.189> about<00:01:35.850> self<00:01:36.180> therapy<00:01:36.570> with<00:01:36.750> autologous

00:01:37.160 --> 00:01:37.170 
trial about self therapy with autologous

00:01:37.170 --> 00:01:39.590 
trial about self therapy with autologous
adult<00:01:37.829> stem<00:01:38.070> cells<00:01:38.430> in<00:01:38.670> austria<00:01:39.090> necrosis<00:01:39.390> of

00:01:39.590 --> 00:01:39.600 
adult stem cells in austria necrosis of

00:01:39.600 --> 00:01:42.190 
adult stem cells in austria necrosis of
femoral<00:01:40.170> head<00:01:40.409> the<00:01:41.369> bioengineering

00:01:42.190 --> 00:01:42.200 
femoral head the bioengineering

00:01:42.200 --> 00:01:44.810 
femoral head the bioengineering
orthopedics<00:01:43.200> and<00:01:43.439> surgery<00:01:43.979> in<00:01:44.220> periodic

00:01:44.810 --> 00:01:44.820 
orthopedics and surgery in periodic

00:01:44.820 --> 00:01:48.130 
orthopedics and surgery in periodic
group<00:01:45.090> is<00:01:45.390> led<00:01:45.780> by<00:01:45.810> dr.<00:01:46.820> photography<00:01:47.820> a--

00:01:48.130 --> 00:01:48.140 
group is led by dr. photography a--

00:01:48.140 --> 00:01:51.740 
group is led by dr. photography a--
Fantasia<00:01:49.140> their<00:01:50.040> experimental<00:01:50.850> studies<00:01:51.450> in

00:01:51.740 --> 00:01:51.750 
Fantasia their experimental studies in

00:01:51.750 --> 00:01:55.190 
Fantasia their experimental studies in
photo<00:01:52.079> scopic<00:01:52.649> approach<00:01:53.460> for<00:01:53.939> intra<00:01:54.600> uterine

00:01:55.190 --> 00:01:55.200 
photo scopic approach for intra uterine

00:01:55.200 --> 00:01:58.039 
photo scopic approach for intra uterine
myelomeningocele<00:01:55.950> repair<00:01:56.360> have<00:01:57.360> allowed

00:01:58.039 --> 00:01:58.049 
myelomeningocele repair have allowed

00:01:58.049 --> 00:02:01.219 
myelomeningocele repair have allowed
them<00:01:58.350> to<00:01:58.890> be<00:01:59.310> more<00:01:59.670> translational<00:02:00.450> and<00:02:00.600> they

00:02:01.219 --> 00:02:01.229 
them to be more translational and they

00:02:01.229 --> 00:02:03.380 
them to be more translational and they
already<00:02:01.530> started<00:02:02.130> this<00:02:02.490> treatment<00:02:02.759> in<00:02:03.210> the

00:02:03.380 --> 00:02:03.390 
already started this treatment in the

00:02:03.390 --> 00:02:05.870 
already started this treatment in the
human<00:02:03.689> fetus<00:02:03.990> with<00:02:04.799> good<00:02:05.100> preliminary

00:02:05.870 --> 00:02:05.880 
human fetus with good preliminary

00:02:05.880 --> 00:02:09.859 
human fetus with good preliminary
results<00:02:06.799> in<00:02:07.799> 2013<00:02:08.789> they<00:02:09.000> also<00:02:09.149> developed<00:02:09.750> a

00:02:09.859 --> 00:02:09.869 
results in 2013 they also developed a

00:02:09.869 --> 00:02:11.770 
results in 2013 they also developed a
new<00:02:10.020> animal<00:02:10.530> model<00:02:10.890> of<00:02:11.069> skeletal<00:02:11.670> muscle

00:02:11.770 --> 00:02:11.780 
new animal model of skeletal muscle

00:02:11.780 --> 00:02:13.690 
new animal model of skeletal muscle
muscle<00:02:12.780> injury

00:02:13.690 --> 00:02:13.700 
muscle injury

00:02:13.700 --> 00:02:16.000 
muscle injury
finally<00:02:14.360> they<00:02:14.540> develop<00:02:14.990> another<00:02:15.440> animal

00:02:16.000 --> 00:02:16.010 
finally they develop another animal

00:02:16.010 --> 00:02:18.640 
finally they develop another animal
model<00:02:16.340> of<00:02:16.930> pharmacokinetics<00:02:17.930> in<00:02:18.140> rabbits

00:02:18.640 --> 00:02:18.650 
model of pharmacokinetics in rabbits

00:02:18.650 --> 00:02:20.530 
model of pharmacokinetics in rabbits
which<00:02:19.190> allow<00:02:19.610> them<00:02:19.880> to<00:02:20.150> study<00:02:20.390> the

00:02:20.530 --> 00:02:20.540 
which allow them to study the

00:02:20.540 --> 00:02:22.570 
which allow them to study the
penetration<00:02:21.170> of<00:02:21.440> antibiotics<00:02:22.160> in<00:02:22.370> the

00:02:22.570 --> 00:02:22.580 
penetration of antibiotics in the

00:02:22.580 --> 00:02:25.390 
penetration of antibiotics in the
infected<00:02:23.120> immature<00:02:23.870> bone<00:02:24.140> the<00:02:25.010> general

00:02:25.390 --> 00:02:25.400 
infected immature bone the general

00:02:25.400 --> 00:02:27.610 
infected immature bone the general
surgery<00:02:25.910> group<00:02:26.180> is<00:02:26.590> coordinated<00:02:27.590> by

00:02:27.610 --> 00:02:27.620 
surgery group is coordinated by

00:02:27.620 --> 00:02:29.920 
surgery group is coordinated by
professor<00:02:27.800> Manuel<00:02:28.790> our<00:02:28.940> main<00:02:29.180> goal<00:02:29.209> Carrasco

00:02:29.920 --> 00:02:29.930 
professor Manuel our main goal Carrasco

00:02:29.930 --> 00:02:32.140 
professor Manuel our main goal Carrasco
the<00:02:30.350> group<00:02:30.560> received<00:02:31.069> two<00:02:31.280> new<00:02:31.430> grants<00:02:31.850> that

00:02:32.140 --> 00:02:32.150 
the group received two new grants that

00:02:32.150 --> 00:02:34.809 
the group received two new grants that
have<00:02:32.360> been<00:02:32.540> awarded<00:02:33.260> from<00:02:33.410> national<00:02:33.890> calls<00:02:34.160> to

00:02:34.809 --> 00:02:34.819 
have been awarded from national calls to

00:02:34.819 --> 00:02:37.330 
have been awarded from national calls to
further<00:02:35.150> investigate<00:02:35.930> the<00:02:36.350> molecular<00:02:36.560> basis

00:02:37.330 --> 00:02:37.340 
further investigate the molecular basis

00:02:37.340 --> 00:02:40.180 
further investigate the molecular basis
of<00:02:37.370> incisional<00:02:38.239> hernia<00:02:38.420> and<00:02:39.020> new<00:02:39.800> surgical

00:02:40.180 --> 00:02:40.190 
of incisional hernia and new surgical

00:02:40.190 --> 00:02:43.780 
of incisional hernia and new surgical
procedures<00:02:40.819> for<00:02:41.360> low<00:02:41.660> rectal<00:02:42.319> cancers<00:02:42.830> the

00:02:43.780 --> 00:02:43.790 
procedures for low rectal cancers the

00:02:43.790 --> 00:02:45.940 
procedures for low rectal cancers the
group<00:02:44.030> has<00:02:44.390> also<00:02:44.420> published<00:02:45.140> its<00:02:45.380> experience

00:02:45.940 --> 00:02:45.950 
group has also published its experience

00:02:45.950 --> 00:02:48.430 
group has also published its experience
as<00:02:46.160> a<00:02:46.220> European<00:02:46.940> center<00:02:47.360> of<00:02:47.540> excellence<00:02:48.050> in

00:02:48.430 --> 00:02:48.440 
as a European center of excellence in

00:02:48.440 --> 00:02:51.340 
as a European center of excellence in
bariatric<00:02:49.280> surgery<00:02:49.730> a<00:02:50.000> patent<00:02:50.959> has<00:02:51.200> been

00:02:51.340 --> 00:02:51.350 
bariatric surgery a patent has been

00:02:51.350 --> 00:02:53.770 
bariatric surgery a patent has been
obtained<00:02:51.769> related<00:02:52.730> to<00:02:52.850> surgical<00:02:53.360> suture

00:02:53.770 --> 00:02:53.780 
obtained related to surgical suture

00:02:53.780 --> 00:02:56.199 
obtained related to surgical suture
instrument<00:02:54.560> for<00:02:54.680> anastomosis<00:02:55.160> of<00:02:55.489> digestive

00:02:56.199 --> 00:02:56.209 
instrument for anastomosis of digestive

00:02:56.209 --> 00:02:58.750 
instrument for anastomosis of digestive
tract<00:02:56.600> the<00:02:57.230> new<00:02:57.410> international<00:02:58.160> networking

00:02:58.750 --> 00:02:58.760 
tract the new international networking

00:02:58.760 --> 00:03:00.610 
tract the new international networking
has<00:02:58.940> been<00:02:59.120> started<00:02:59.660> with<00:02:59.810> a<00:02:59.840> Max<00:03:00.200> Planck

00:03:00.610 --> 00:03:00.620 
has been started with a Max Planck

00:03:00.620 --> 00:03:02.740 
has been started with a Max Planck
Institute<00:03:00.799> for<00:03:01.549> intelligent<00:03:02.090> systems<00:03:02.569> and

00:03:02.740 --> 00:03:02.750 
Institute for intelligent systems and

00:03:02.750 --> 00:03:05.220 
Institute for intelligent systems and
has<00:03:03.380> been<00:03:03.560> recently<00:03:04.069> recognized<00:03:04.670> as

00:03:05.220 --> 00:03:05.230 
has been recently recognized as

00:03:05.230 --> 00:03:07.110 
has been recently recognized as
consolidated<00:03:06.230> by<00:03:06.410> the<00:03:06.470> Catalan<00:03:06.920> government

00:03:07.110 --> 00:03:07.120 
consolidated by the Catalan government

00:03:07.120 --> 00:03:10.270 
consolidated by the Catalan government
the<00:03:08.120> genetics<00:03:08.720> research<00:03:09.260> group<00:03:09.560> is<00:03:09.830> led<00:03:10.250> by

00:03:10.270 --> 00:03:10.280 
the genetics research group is led by

00:03:10.280 --> 00:03:13.990 
the genetics research group is led by
dr.<00:03:10.930> alberto<00:03:11.930> plaza<00:03:12.260> and<00:03:12.769> the<00:03:13.580> group<00:03:13.790> is

00:03:13.990 --> 00:03:14.000 
dr. alberto plaza and the group is

00:03:14.000 --> 00:03:16.509 
dr. alberto plaza and the group is
evaluating<00:03:14.989> the<00:03:15.140> impact<00:03:15.530> of<00:03:15.739> the<00:03:16.130> fetal

00:03:16.509 --> 00:03:16.519 
evaluating the impact of the fetal

00:03:16.519 --> 00:03:19.330 
evaluating the impact of the fetal
alcohol<00:03:16.700> syndrome<00:03:17.390> spectrum<00:03:18.200> disorders<00:03:18.739> in<00:03:19.220> a

00:03:19.330 --> 00:03:19.340 
alcohol syndrome spectrum disorders in a

00:03:19.340 --> 00:03:21.280 
alcohol syndrome spectrum disorders in a
population<00:03:19.760> of<00:03:20.060> children<00:03:20.630> coming<00:03:21.140> from

00:03:21.280 --> 00:03:21.290 
population of children coming from

00:03:21.290 --> 00:03:24.310 
population of children coming from
international<00:03:22.160> adoption<00:03:22.760> in<00:03:22.880> Spain<00:03:23.290> they<00:03:24.290> are

00:03:24.310 --> 00:03:24.320 
international adoption in Spain they are

00:03:24.320 --> 00:03:26.560 
international adoption in Spain they are
exploring<00:03:24.920> the<00:03:25.250> frequency<00:03:25.850> of<00:03:26.090> genomic

00:03:26.560 --> 00:03:26.570 
exploring the frequency of genomic

00:03:26.570 --> 00:03:29.170 
exploring the frequency of genomic
rearrangements<00:03:27.560> and<00:03:27.680> the<00:03:28.250> causality<00:03:28.700> for

00:03:29.170 --> 00:03:29.180 
rearrangements and the causality for

00:03:29.180 --> 00:03:31.000 
rearrangements and the causality for
congenital<00:03:29.750> heart<00:03:29.959> disease<00:03:30.380> they<00:03:30.739> are<00:03:30.829> also

00:03:31.000 --> 00:03:31.010 
congenital heart disease they are also

00:03:31.010 --> 00:03:33.150 
congenital heart disease they are also
collaborating<00:03:31.459> in<00:03:32.090> specialized<00:03:32.750> and

00:03:33.150 --> 00:03:33.160 
collaborating in specialized and

00:03:33.160 --> 00:03:36.009 
collaborating in specialized and
multidisciplinary<00:03:34.160> clinics<00:03:34.579> such<00:03:35.209> as<00:03:35.450> Marvin

00:03:36.009 --> 00:03:36.019 
multidisciplinary clinics such as Marvin

00:03:36.019 --> 00:03:38.560 
multidisciplinary clinics such as Marvin
Williams<00:03:36.590> syndrome<00:03:37.010> fatal<00:03:37.910> medicine<00:03:38.359> and

00:03:38.560 --> 00:03:38.570 
Williams syndrome fatal medicine and

00:03:38.570 --> 00:03:42.310 
Williams syndrome fatal medicine and
short<00:03:39.170> stature<00:03:39.530> clinic<00:03:40.329> finally<00:03:41.329> they<00:03:42.079> have<00:03:42.290> a

00:03:42.310 --> 00:03:42.320 
short stature clinic finally they have a

00:03:42.320 --> 00:03:44.800 
short stature clinic finally they have a
bioinformatics<00:03:43.040> and<00:03:43.640> technical<00:03:44.180> project<00:03:44.660> to

00:03:44.800 --> 00:03:44.810 
bioinformatics and technical project to

00:03:44.810 --> 00:03:47.170 
bioinformatics and technical project to
facilitate<00:03:45.410> interpretation<00:03:46.280> and<00:03:46.519> lower<00:03:46.820> cost

00:03:47.170 --> 00:03:47.180 
facilitate interpretation and lower cost

00:03:47.180 --> 00:03:51.130 
facilitate interpretation and lower cost
of<00:03:47.450> array<00:03:48.019> CGH<00:03:48.910> technique<00:03:49.910> the<00:03:50.450> maternal

00:03:51.130 --> 00:03:51.140 
of array CGH technique the maternal

00:03:51.140 --> 00:03:54.460 
of array CGH technique the maternal
fetal<00:03:51.530> medicine<00:03:51.950> research<00:03:52.910> group<00:03:53.390> is<00:03:53.660> led<00:03:54.170> by

00:03:54.460 --> 00:03:54.470 
fetal medicine research group is led by

00:03:54.470 --> 00:03:57.309 
fetal medicine research group is led by
Professor<00:03:55.070> cavero<00:03:55.489> and<00:03:55.810> doctora<00:03:56.900> Elena

00:03:57.309 --> 00:03:57.319 
Professor cavero and doctora Elena

00:03:57.319 --> 00:04:00.940 
Professor cavero and doctora Elena
kuvira's<00:03:57.829> the<00:03:58.579> most<00:03:58.850> prominent<00:03:59.840> task<00:04:00.230> of<00:04:00.560> this

00:04:00.940 --> 00:04:00.950 
kuvira's the most prominent task of this

00:04:00.950 --> 00:04:02.650 
kuvira's the most prominent task of this
group<00:04:01.220> has<00:04:01.609> been<00:04:01.640> the<00:04:02.060> international

00:04:02.650 --> 00:04:02.660 
group has been the international

00:04:02.660 --> 00:04:05.349 
group has been the international
diffusion<00:04:03.230> of<00:04:03.380> the<00:04:03.890> use<00:04:04.069> of<00:04:04.370> the<00:04:04.640> pessary<00:04:05.030> as<00:04:05.329> a

00:04:05.349 --> 00:04:05.359 
diffusion of the use of the pessary as a

00:04:05.359 --> 00:04:07.990 
diffusion of the use of the pessary as a
useful<00:04:05.870> tool<00:04:06.079> to<00:04:06.290> prevent<00:04:06.680> preterm<00:04:07.489> birth

00:04:07.990 --> 00:04:08.000 
useful tool to prevent preterm birth

00:04:08.000 --> 00:04:10.750 
useful tool to prevent preterm birth
they<00:04:08.989> are<00:04:09.170> also<00:04:09.470> working<00:04:09.980> on<00:04:10.370> the

00:04:10.750 --> 00:04:10.760 
they are also working on the

00:04:10.760 --> 00:04:12.750 
they are also working on the
relationship<00:04:11.480> between<00:04:11.510> angio<00:04:12.290> genic

00:04:12.750 --> 00:04:12.760 
relationship between angio genic

00:04:12.760 --> 00:04:15.039 
relationship between angio genic
anti-angiogenic<00:04:13.760> factors<00:04:13.790> misbalance

00:04:15.039 --> 00:04:15.049 
anti-angiogenic factors misbalance

00:04:15.049 --> 00:04:17.650 
anti-angiogenic factors misbalance
and<00:04:15.170> nuchal<00:04:15.680> translucency<00:04:15.789> and<00:04:16.789> congenital

00:04:17.650 --> 00:04:17.660 
and nuchal translucency and congenital

00:04:17.660 --> 00:04:20.770 
and nuchal translucency and congenital
heart<00:04:18.109> disease<00:04:18.530> the<00:04:19.400> new<00:04:19.609> technologies<00:04:20.479> and

00:04:20.770 --> 00:04:20.780 
heart disease the new technologies and

00:04:20.780 --> 00:04:22.839 
heart disease the new technologies and
micro<00:04:21.109> surgery<00:04:21.410> in<00:04:21.680> craniofacial<00:04:22.190> surgery

00:04:22.839 --> 00:04:22.849 
micro surgery in craniofacial surgery

00:04:22.849 --> 00:04:25.779 
micro surgery in craniofacial surgery
group<00:04:23.150> is<00:04:23.599> led<00:04:23.930> by<00:04:23.960> dr.<00:04:24.470> ax<00:04:24.950> this<00:04:25.430> course

00:04:25.779 --> 00:04:25.789 
group is led by dr. ax this course

00:04:25.789 --> 00:04:27.040 
group is led by dr. ax this course
focused<00:04:26.390> on

00:04:27.040 --> 00:04:27.050 
focused on

00:04:27.050 --> 00:04:28.809 
focused on
the<00:04:27.229> development<00:04:27.860> of<00:04:28.099> new<00:04:28.310> image

00:04:28.809 --> 00:04:28.819 
the development of new image

00:04:28.819 --> 00:04:31.719 
the development of new image
technologies<00:04:29.539> virtual<00:04:30.229> planning<00:04:30.729> navigation

00:04:31.719 --> 00:04:31.729 
technologies virtual planning navigation

00:04:31.729 --> 00:04:34.540 
technologies virtual planning navigation
and<00:04:31.970> robotic<00:04:32.720> surgery<00:04:32.979> together<00:04:33.979> with<00:04:34.430> the

00:04:34.540 --> 00:04:34.550 
and robotic surgery together with the

00:04:34.550 --> 00:04:36.399 
and robotic surgery together with the
development<00:04:35.120> of<00:04:35.240> microsurgery<00:04:35.840> as<00:04:36.349> a

00:04:36.399 --> 00:04:36.409 
development of microsurgery as a

00:04:36.409 --> 00:04:39.059 
development of microsurgery as a
reconstructive<00:04:37.400> technique<00:04:37.849> in<00:04:38.210> cranial

00:04:39.059 --> 00:04:39.069 
reconstructive technique in cranial

00:04:39.069 --> 00:04:41.800 
reconstructive technique in cranial
maxillofacial<00:04:40.069> surgery<00:04:40.520> and<00:04:40.789> finally<00:04:41.599> the

00:04:41.800 --> 00:04:41.810 
maxillofacial surgery and finally the

00:04:41.810 --> 00:04:43.899 
maxillofacial surgery and finally the
ophthalmology<00:04:42.500> research<00:04:42.919> group<00:04:43.220> led<00:04:43.490> by

00:04:43.899 --> 00:04:43.909 
ophthalmology research group led by

00:04:43.909 --> 00:04:46.240 
ophthalmology research group led by
Professor<00:04:44.389> Jose<00:04:44.780> Garcia<00:04:45.139> Lumi<00:04:45.440> mainly

00:04:46.240 --> 00:04:46.250 
Professor Jose Garcia Lumi mainly

00:04:46.250 --> 00:04:48.460 
Professor Jose Garcia Lumi mainly
centred<00:04:46.729> on<00:04:46.879> retinal<00:04:47.629> vascular<00:04:48.020> disease

00:04:48.460 --> 00:04:48.470 
centred on retinal vascular disease

00:04:48.470 --> 00:04:50.890 
centred on retinal vascular disease
including<00:04:49.460> the<00:04:49.729> physio<00:04:50.120> pathology<00:04:50.690> of

00:04:50.890 --> 00:04:50.900 
including the physio pathology of

00:04:50.900 --> 00:04:53.800 
including the physio pathology of
diabetic<00:04:51.620> retinopathy<00:04:52.270> visual<00:04:53.270> pathology

00:04:53.800 --> 00:04:53.810 
diabetic retinopathy visual pathology

00:04:53.810 --> 00:04:55.270 
diabetic retinopathy visual pathology
and<00:04:53.900> treatment<00:04:54.319> of<00:04:54.440> retinal<00:04:54.770> vein<00:04:55.220> occlusion

00:04:55.270 --> 00:04:55.280 
and treatment of retinal vein occlusion

00:04:55.280 --> 00:04:58.300 
and treatment of retinal vein occlusion
and<00:04:56.030> new<00:04:56.539> treatments<00:04:57.050> of<00:04:57.169> retinal<00:04:57.770> artery

00:04:58.300 --> 00:04:58.310 
and new treatments of retinal artery

00:04:58.310 --> 00:05:00.819 
and new treatments of retinal artery
occlusion

